Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients

LIVONIA, Mich., June 28, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ:GEMP) today announced top-line data on the LDL-C primary endpoint from the completed open label Phase 2b COBALT-1 trial. COBALT-1 evaluated gemcabene in homozygous...

Source: Drugs.com - Clinical Trials - June 28, 2017 Category: Pharmaceuticals Source Type: clinical trials